The pharmacokinetics of linezolid in the non-inflamed human eye

British Journal of Ophthalmology

Volumn 89, Issue 11, 2005, Pages 1418-1419

  Prydal, Jeremy I ^a   Jenkins, D R ^a   Lovering, A ^b   Watts, A ^a  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; LINEZOLID; OXAZOLIDINONE DERIVATIVE;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG PENETRATION; ENDOPHTHALMITIS; FEMALE; GRAM POSITIVE BACTERIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NONHUMAN; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ACETAMIDES; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; AQUEOUS HUMOR; CATARACT EXTRACTION; ENDOPHTHALMITIS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES;

EID: 27344440151     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2005.073700     Document Type: Article

References (12)

1. Javitt JC, Vitale S, Canner JK, et al. National outcomes of cataract extraction. Endophthalmitis following in-patient surgery. Arch Ophthalmol 1991;109:1085-9.
2. Fisch A, Salvanet A, Prazuck T, et al. Epidemiology of infective endophthalmitis in France. Lancet 1991;338:1373-6.
3. Norregaard JC, Thoning H, Bernth-Petersen P, et al. Risk of endophthalmitis after cataract extraction: results from the International Cataract Surgery Outcome study. Br J Ophthalmol 1997;81:102-6.
4. Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the endophthalmitis vitrectomy study. Am J Ophthalmol 1996;122:1-17.
5. Endophthalmitis Vitrectomy Study Group. Results of the endophthalmitis vitrectomy study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995;113:1479-96.
6. Okhravi N, Towler HMA, Hykin P, et al. Assessment of a standard treatment protocol on visual outcome following presumed bacterial endophthalmitis. Br J Ophthalmol 1997;81:719-25.
7. Clemett D, Markham A. Linezolid. Drugs 2000;59:815-28.
8. Johnson AP, Warner M, Livermore DM. Activity of linezolid against multi-resistant Gram-positive bacteria from diverse hospitals in the United Kingdom. J Antimicrob Chemother 2000;45:225-30.
9. Layering AM, Zhang G, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002;50:73-77.
10. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003;51(Suppl S2):ii17-25.
11. García Vázquez E, Mensa J, López Y, et al. Penetration of linezolid into the anterior chamber (aqueous humour) of the human eye after intravenous administration. Antimicrob Agents Chemother 2004;48:670-2.
12. Fiscella RG, Lai WW, Buerk B, et al. Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration. Ophthalmology 2004;111:1191-5.